Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has been assigned a consensus recommendation of “Hold” from the twenty-nine research firms that are presently covering the company, Marketbeat.com reports. Two research analysts have rated the stock with a sell recommendation, thirteen have given a hold recommendation, twelve have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $492.95.

Several equities analysts recently issued reports on the company. J P Morgan Chase & Co reiterated a “hold” rating on shares of Regeneron Pharmaceuticals in a research report on Tuesday, August 15th. Robert W. Baird downgraded Regeneron Pharmaceuticals from a “neutral” rating to an “underperform” rating and set a $408.00 price target for the company. in a research report on Tuesday, August 8th. Goldman Sachs Group, Inc. (The) reaffirmed a “neutral” rating and set a $472.00 price target (up previously from $469.00) on shares of Regeneron Pharmaceuticals in a research report on Wednesday, August 9th. Zacks Investment Research raised Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $540.00 price target for the company in a research report on Wednesday, August 9th. Finally, Leerink Swann reaffirmed an “outperform” rating and set a $580.00 price target (up previously from $573.00) on shares of Regeneron Pharmaceuticals in a research report on Wednesday, August 9th.

In other Regeneron Pharmaceuticals news, SVP Michael S. Aberman sold 2,269 shares of the stock in a transaction on Thursday, June 22nd. The stock was sold at an average price of $532.42, for a total transaction of $1,208,060.98. Following the transaction, the senior vice president now owns 9,193 shares in the company, valued at approximately $4,894,537.06. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Robert E. Landry sold 189 shares of the stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $501.06, for a total value of $94,700.34. Following the transaction, the chief financial officer now owns 10,099 shares in the company, valued at approximately $5,060,204.94. The disclosure for this sale can be found here. Insiders have sold a total of 99,543 shares of company stock worth $47,831,369 in the last quarter. Company insiders own 10.40% of the company’s stock.

A number of hedge funds have recently bought and sold shares of the business. Intl Fcstone Inc. bought a new position in Regeneron Pharmaceuticals during the 2nd quarter worth $346,000. Lord Abbett & CO. LLC bought a new position in Regeneron Pharmaceuticals during the 2nd quarter worth $51,931,000. Toronto Dominion Bank increased its position in Regeneron Pharmaceuticals by 25.8% during the 2nd quarter. Toronto Dominion Bank now owns 25,835 shares of the biopharmaceutical company’s stock worth $12,686,000 after buying an additional 5,295 shares during the period. WINTON GROUP Ltd bought a new position in Regeneron Pharmaceuticals during the 2nd quarter worth $713,000. Finally, Public Employees Retirement System of Ohio increased its position in Regeneron Pharmaceuticals by 1.6% during the 2nd quarter. Public Employees Retirement System of Ohio now owns 54,288 shares of the biopharmaceutical company’s stock worth $26,663,000 after buying an additional 867 shares during the period. Hedge funds and other institutional investors own 67.96% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This story was posted by American Banking News and is the property of of American Banking News. If you are reading this story on another website, it was illegally copied and republished in violation of US and international copyright and trademark laws. The original version of this story can be accessed at https://www.americanbankingnews.com/2017/09/16/regeneron-pharmaceuticals-inc-regn-given-average-rating-of-hold-by-analysts.html.

Regeneron Pharmaceuticals (NASDAQ REGN) traded down 1.77% during mid-day trading on Friday, hitting $433.45. 1,002,422 shares of the company traded hands. Regeneron Pharmaceuticals has a one year low of $325.35 and a one year high of $543.55. The company has a market capitalization of $45.96 billion, a price-to-earnings ratio of 43.48 and a beta of 1.65. The company’s 50-day moving average price is $472.80 and its 200 day moving average price is $445.37.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported $4.17 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.67 by $1.50. Regeneron Pharmaceuticals had a return on equity of 25.58% and a net margin of 22.05%. The business had revenue of $1.47 billion during the quarter, compared to analyst estimates of $1.36 billion. During the same period in the previous year, the firm earned $2.82 EPS. Regeneron Pharmaceuticals’s quarterly revenue was up 21.2% compared to the same quarter last year. On average, analysts anticipate that Regeneron Pharmaceuticals will post $14.90 earnings per share for the current fiscal year.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.